and the main guidelines do not give conclusive indications on the matter. The American Heart Association/ American Diabetes Association support aspirin use for diabetes patients with intermediate risk for primary prevention. 5 On the other hand, the European Society of Cardiology guidelines recommend against aspirin use in patients with diabetes who do not have any prior history of established CVD. 6 Moreover there is reduced availability of data from the sparse primary prevention trials already conducted, most of which recruited individuals with low cardiovascular risk. A meta-analysis of individual participant data from six randomised studies, published in 2009, showed that the decrease in vascular events after aspirin therapy is burdened by increased bleeding and haemorrhagic stroke rates. 7 To this topic, still a cause of controversy, the metaanalysis of Upadhaya et al., 8 published in the European Journal of Preventive Cardiology, brings further scientific evidence. This meta-analysis was designed in order to assess the risks and benefits of aspirin for primary prevention of CVD. The pooled outcomes for efficacy were cardiovascular death, ischaemic stroke (both fatal and non-fatal), non-fatal stroke, non-fatal MI, allcause mortality, colorectal cancer incidence and allcancer incidence. The pooled outcomes for safety were major bleeding, major gastrointestinal bleeding and haemorrhagic stroke (both fatal and non-fatal). A total of 165,512 patients was included in this study. The authors found a significant reduction in non-fatal MI and ischaemic stroke in participants taking aspirin. However, they did not find a significant difference in CVD death, all-cause mortality and non-fatal stroke. Moreover, the authors found a significant increment in the rates of major bleeding, and major gastrointestinal bleeding in patients who received aspirin, but no significant difference in the rate of haemorrhagic stroke. Interestingly, when only studies with more than 10 years of follow-up were included, the colorectal cancer incidence became significantly lower in patient taking aspirin. Finally, the authors did not find a significant difference in all-cancer incidence between the two groups. The authors concluded that 'the use of ASA for primary prevention was associated with significantly higher risk of major bleeding, lower risk of colorectal cancer, non-fatal MI and ischemic stroke, and no difference in CVD death compared to placebo'.
The effects of aspirin in preventing CVDs are well known and widely studied and explained. 9 Briefly, aspirin irreversibly inactivates cyclooxygenase-1, with a consequent decrease in the biosynthesis of prostaglandin H2 and thromboxane A2. 10 Suppression of thromboxane A2 production inhibits platelet aggregation, a fundamental event in coronary thrombosis and acute MI. It is also well known that aspirin suppresses many lipid mediators released by activated platelets through pathways dependent on cyclooxygenase-1. These mechanisms could counteract the progression of normal colonic mucosa to adenoma and to carcinoma. 11 However, aspirin-mediated cyclooxygenase-1 inhibition also leads to mucosal damage in the gastrointestinal tract and, in conjunction with aspirin's antiplatelet effect, increases gastrointestinal bleeding and haemorrhagic stroke. These are the reasons why the use of aspirin for the primary prevention of cardiovascular events in the absence of a history of CVD is still a topic of debate.
The results of this paper published shed further light on the role of aspirin in the primary prevention of CVDs, and they are substantially consistent with two recent studies that have thrown water on the fire of enthusiasm deriving from the use of aspirin in primary prevention.
In fact, the ASCEND 12 and ARRIVE 13 studies were designed with this aim, in order to evaluate the efficacy and safety of daily intake of aspirin 100 mg versus placebo tablets, respectively, in individuals with diabetes (ASCEND study), or patients with a moderate risk of the first acute cardiovascular event (ARRIVE study). The ASCEND study (A Study of Cardiovascular Events iN Diabetes) showed that aspirin every day reduces the risk of the first cardiovascular event in high-risk diabetes patients but also that the benefit is counterbalanced by the risk of bleeding. 1 The ARRIVE study, published simultaneously in the Lancet, has not been able to document a benefit of the primary preventive intake of aspirin every day in non-diabetic and lowrisk cardiovascular subjects. 2 The results of the ASCEND study have shown that, when looking at the risk-benefit balance, the absolute benefit of the reduction of serious vascular events, obtained with aspirin, is largely counterbalanced by the increased risk of bleeding. Furthermore, it was not possible to identify a group of patients in the trial in which it was possible to observe a risk-benefit ratio in favour of the latter.
The researchers, moreover, also stressed that most of the 15,840 patients of the trial were subjected to a good control of the other cardiovascular risk factors, with high rates of treatment with statins and antihypertensive drugs, good glycaemic control and a reduced rate of smoking.
Based on the results of this study on the use of aspirin in the primary prevention of CVDs in diabetes patients, the mere presence of diabetes, therefore, does not seem sufficient to give aspirin a favourable riskbenefit profile. However, it should also be considered that most of the individuals recruited in the study were at low risk, so it would be better to focus on those at higher risk, both in this and in other trials before definitively excluding a role of aspirin in primary diabetes prevention. In light of the results of the ASCEND study, if the patient is well managed for the diabetic condition, as well as for other cardiovascular risk factors, it is useful to evaluate very carefully the risk-benefit profile of aspirin, involving the patient in the subsequent decision-making process.
The results of the ARRIVE study are partly overlapping with those from many other studies that have documented the ability of acetylsalicylic acid (ASA) to reduce the risk of first non-fatal MI, without affecting instead the total risk of stroke. The ARRIVE results did not show an advantage of using aspirin to reduce major cardiovascular events. However, it should also be remembered that the recorded cardiovascular events were well below expectations, underlining that this was a low-risk population. One potential explanation is that some trial participants were already taking antihypertensive and hypolipidaemic drugs, known for their cardioprotective effect.
Adherence to guidelines in aspirin prescription remains a matter of debate, 14 particularly in consideration of the potential incorporation of the results of these trials into the next guidelines.
Probably the use of new biomarkers or coronary calcium scores could help clinicians to identify highrisk patients who benefit from daily aspirin therapy; however, further studies on this matter are warranted.
In conclusion, in light of current knowledge, the routine use of aspirin for primary prevention needs to be reconsidered.
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